Hybrid models identified a 12-gene signature for lung cancer prognosis and chemoresponse prediction

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Wan, Ying Wooi ^a   Sabbagh, Ebrahim ^a   Raese, Rebecca ^a   Qian, Yong ^b   Luo, Dajie ^a   Denvir, James ^a   Vallyathan, Val ^b   Castranova, Vincent ^b   Guo, Nancy Lan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ERLOTINIB; ETOPOSIDE; EXPORTIN 1; GEFITINIB; GENE PRODUCT; MESSENGER RNA; PACLITAXEL; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN ATP6V0D1; PROTEIN CCDC99; PROTEIN DLC1; PROTEIN FAM164A; PROTEIN LMF1; PROTEIN PKLR; PROTEIN SCLY; PROTEIN SMPD1; PROTEIN STK24; PROTEIN ZAK; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; BAYESIAN LEARNING; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC SELECTION; HUMAN; LUNG ADENOCARCINOMA; MALE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR RECURRENCE; ADENOCARCINOMA; BIOLOGICAL MODEL; DRUG RESISTANCE; GENETIC MARKER; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM STAGING; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957877214     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012222     Document Type: Article

References (37)

1. American Cancer Society (2005) Cancer Facts and Figures 2005. AtlantaGa: American Cancer Society.
2. Naruke T, Goya T, Tsuchiya R, Suemasu K (1988) Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 96: 440-447.
3. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355: 479-485.
4. Dalton WS, Friend SH (2006) Cancer biomarkers-an invitation to the table. Science 312: 1165-1168.
5. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
6. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
7. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
8. Hood L, Heath JR, Phelps ME, Lin B (2004) Systems biology and new technologies enable predictive and preventative medicine. Science 306: 640-643.
9. Baker SG, Kramer BS, Srivastava S (2002) Markers for early detection of cancer: statistical guidelines for nested case-control studies. BMC Med Res Methodol 2: 4.
10. Emir B, Wieand S, Su JQ, Cha S (1998) Analysis of repeated markers used to predict progression of cancer. Stat Med 17: 2563-2578.
11. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159: 882-890.
12. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, et al. (2002) Geneexpression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8: 816-824.
13. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 98: 13790-13795.
14. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
15. Borczuk AC, Kim HK, Yegen HA, Friedman RA, Powell CA (2005) Lung adenocarcinoma global profiling identifies type II transforming growth factorbeta receptor as a repressor of invasiveness. Am J Respir Crit Care Med 172: 729-737.
16. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al. (2007) A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356: 11-20.
17. Potti A, Mukherjee S, Petersen R, Dressman HK, Bild A, et al. (2006) A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355: 570-580.
18. Raponi M, Zhang Y, Yu J, Chen G, Lee G, et al. (2006) Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66: 7466-7472.
19. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, et al. (2008) Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
20. Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 102: 464-474.
21. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
22. Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, et al. (2006) A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med 3: e467.
23. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, et al. (2009) Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci U S A 106: 2824-2828.
24. Guo L, Ma Y, Ward R, Castranova V, Shi X, et al. (2006) Constructing molecular classifiers for the accurate prognosis of lung adenocarcinoma. Clin Cancer Res 12: 3344-3354.
25. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, et al. (2007) Threegene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25: 5562-5569.
26. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, et al. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
27. Guo NL, Wan Y, Tosun K, Lin H, Flynn DC, et al. (2008) Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res 14: 8213-8220.
28. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
29. Hall MA, Holmes G (2003) Benchmarking Attribute Selection Techniques for Discrete Class Data Mining. IEEE Transactions on Knowledge and Data Engineering 15: 1437-1447.
30. Witten IH, Frank E (2005) Data Mining: Practical Machine Learning Tools and Techniques (2nd Edition) Morgan Kaufmann.
31. Mitchell, Tom M (1997) Machine Learning McGraw Hill. pp 413.
32. Witten IH, Frank E (2005) Data Mining: Practical Machine Learning Tools and Techniques (2nd Edition) Morgan Kaufmann.
33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102: 15545-15550.
34. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, et al. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6: 820-832.
35. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F (2004) A Model-Based Background Adjustment for Oligonucleotide Expression Arrays. Journal of the American Statistical Association 99: 909.
36. Ma Y, Ding Z, Qian Y, Wan Y, Tosun K, et al. (2009) An Integrative Genomic and Proteomic Approach to Chemosensitivity Prediction. Int J Oncol. pp 107-115.
37. Ma Y, Ding Z, Qian Y, Shi X, Castranova V, et al. (2006) Predicting cancer drug response by proteomic profiling. Clin Cancer Res 12: 4583-4589.